Luminal Versus Non-luminal Breast Cancer CDH1 Immunohistochemical Expression

Abstract

We investigated the immunohistochemical expression of E-cadherin (product of CDH1 gene) and its correlation with clinical-pathological parameters and survival rate in the molecular groups of breast cancer. Our study included female breast cancer patients diagnosed at the Municipal Emergency Clinical Hospital Timisoara followed up five years since diagnosis using formalin fixed paraffin embedded tissue. The traditional prognostic factors (age, tumor size, histological type, histological grade, anatomical status of the lymph nodes) were abstracted from histopathology reports and we set prognostic index (the Nothingham and lymph-node prognosis index). Molecular classification on selected cases was performed in agreement with data from the literature: luminal A, B, HER2+, triple-negative. We noted positive (membranar) expressions in 43 cases (70.49 %). Negative immunoreactions for E-cadherin have been observed in all cases of lobular carcinomas (4 cases), as well as 6 cases of mixed carcinomas. A significant correlation was found between E-cadherin expression and hormonal status, tumor size, histologic type, tumor grade and molecular subtype. Most of the luminal A and B tumors were E-cadherin positive, while more than half of non-luminal tumors were E-cadherin negative. Survival rates are different in the negative and positive E-cadherin tumor groups respectively and between luminal and non-luminal groups. E-cadherin expression may be a useful prognostic marker for classifying other subgroups of breast cancer.

Obesity control and liver health in breast cancer: Normalized hepatic elasticity after ketogenic diet

“…Activated partial thromboplastin clotting time (aPTT) is another assay that characterizes coagulation of the blood. Its value's reference range is between 30 s and 50 s [ 12 ]. Aspartate aminotransferase to platelet ratio index (APRI = {(AST/AST upper limit of normal range) x 100}/platelet count (109/L)) is supposed to be a novel accurate index for the prediction of significant fibrosis and cirrhosis [ [13] , [14] , [15] , [16] , [17] , [18] , [19] ].…”

Overview of the anticancer activity of withaferin A, an active constituent of the Indian ginseng Withania somnifera

“…Besides the particular action, E- cadherin transduces signals from the extracellular field through the cytoplasmic end in the nucleus, modifying the gene expression. Epithelial morphology decreases and high invasiveness (meaning advanced phase, high grade and poor prediction/prognosis) is associated with the decrease or complete lack of E-cadherin found in various types of cancer (Zaha et al 2019). Lee et al (2010) demonstrated the inhibitory action of WA on activating the signal transducer; also, the activating role of transcription 3 in human breast cancer cells has been identified.…”

Classifying Breast Cancer Molecular Subtypes by Using Deep Clustering Approach

“…Moreover, Primary and Proliferous tumors have wild-type TP53. One of their most significant genes is CDH1, which is highly expressed in the luminal A and luminal B subtypes, while it has low activity in HER2 − positive and basal − like subtypes (Zaha et al, 2019). However, the higher rate of PR positive than PR negative in the Primary and Proliferous subtypes may differ from LuminalB tumors.…”